Bloomberg reports that employer coverage of GLP-1 weight loss drugs is shrinking, leaving fewer US workers with access through their health plans.
Recap by typeshit. Full story at Bloomberg.
Pharmacist Paige notes the second round of Medicare drug price negotiation starts January 1, 2027, with the semaglutide family on the list.
New generics and steady prices drove the jump in sales value, with Eli Lilly's tirzepatide leading the market.
UBS says volumes grew about 55% while net prices fell roughly 14%, and points to about 500,000 people joining Lilly's Medicare bridge program in a few months.
A new market report values the sector at $97.5 billion in 2025 and expects oral and multi-pathway drugs to grow fastest as Medicare coverage starts in mid-2026.
A short clip from a surgical practice on why some people lose weight everywhere but their legs on GLP-1 drugs.
The peptide item sits among gene therapy, Neuralink and Medicare news. The Alliance for Safe Biologic Medicines has asked HHS to pause the policy, citing FDA scientists.
Loading…